ACCC launches new initiative to facilitate adoption of immuno-oncology in community cancer setting

NewsGuard 100/100 Score

Institute for Clinical Immuno-Oncology Helps Community Providers Integrate New Treatment Paradigm into Practice

The Association of Community Cancer Centers (ACCC) today launches the Institute for Clinical Immuno-Oncology (ICLIO), the first of its kind initiative aimed to rapidly facilitate the adoption of immuno-oncology in the community cancer setting.

Immuno-oncology (I-O), a transformational paradigm in cancer treatment, puts the body’s own immune system to work to fight cancer. To help with the rapid uptake of I-O at the community level, the ACCC developed ICLIO as the premier source for I-O implementation resources. ICLIO enables medical professionals to offer their patients cutting-edge cancer care by educating on the best practices for I-O integration into all aspects of care: clinical care, deciphering reimbursement, insurance, social work, and supporting patient access to emerging treatment options.

“I-O is becoming increasingly integral to cancer treatment, and education on its adoption in clinical practice is a critical need for providers and patients,” said Lee S. Schwartzberg, MD, FACP, and chair of ICLIO. “ICLIO resources will help guide multidisciplinary cancer teams through the practical application of immunotherapy to provide the best care possible for cancer patients.”

ICLIO educational tools focus on five primary domains: clinical optimization, coverage and reimbursement, management best practices, patient access and advocacy, and training and development. ICLIO is open to all providers through ACCC, whose membership boasts more than 2,000 cancer programs and 20,000 providers nationwide. It is estimated that more than 60 percent of all cancer patients in the U.S. are treated by someone in the ACCC network.

“ACCC is committed to being a leader in cancer care education by providing the most up-to-date and innovative cancer treatment resources and information to our members,” said ACCC President Steven L. D’Amato, BSPharm, BCOP. “We recognize the critical need for offering immunotherapy in community cancer centers and established ICLIO to empower cancer care providers to address the dynamic intricacies of I-O real-world treatment and delivery.”

The ICLIO website is now live at accc-iclio.org, offering a wealth of resources. ICLIO will host its First Annual National Conference in Philadelphia, PA on October 2, 2015 to explore the challenges and opportunities within the emerging clinical and operational applications of cancer immunotherapy.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy